Skip to main content
Premium Trial:

Request an Annual Quote

AB Sciex Posts Strong Q4 Sales as Academic, Research Markets Grow at Double-Digit Rates


This story originally ran on Jan. 31.

Danaher this week reported a 38 percent increase in its fourth-quarter revenues, with its AB Sciex business growing at a low double-digit rate.

On a conference call to discuss the financial results, Danaher CEO Larry Culp said AB Sciex's growth was driven by continued uptake of the company's TripleTOF 5600 mass spectrometer and was broad based, "with academic, applied, and research markets all growing in excess of 10 percent."

He added that AB Sciex had seen over 500 basis points of improvement in its operating margins in 2011.

Culp cautioned, however, that despite the strong end of the year for the firm's mass spec business, uncertainty still surrounds both the academic and government and pharma markets.

"We're clearly not banking on anything that's government-funded being particularly robust," he said, noting that China and Germany could prove exceptions. He added that "we always watch the pharma end market with a conservative posture just given some of the issues that [firms] are going through [with] the resets of R&D spend and R&D operations."

For the quarter, sales for Danaher's Life Sciences & Diagnostics segment, which houses AB Sciex, increased to $1.73 billion, compared to $682.1 million a year ago, before it acquired Beckman Coulter.

Total sales rose to $4.72 billion from $3.43 billion, short of Wall Street estimates of $4.75 billion. Core revenues grew 4 percent year over year.

Danaher's profit for the quarter was $570.7 million, or $.80 per share, compared to a profit of $473.9 million, or $.69 per share, a year ago. The company said that adjusted EPS from continuing operations for the quarter was $.81.

R&D costs for the quarter were $282.1 million, a 33 percent increase from $212.2 million from a year ago.

For full-year 2011, Danaher's sales grew to $16.1 billion, a 28 percent increase from $12.6 billion in 2010, as Life Sciences & Diagnostics rose to $4.63 billion from $2.3 billion. Core revenues companywide grew 7 percent year over year.

The company's profits rose in 2011 to $2.17 billion, or $3.11 per share, up from $1.79 billion, or $2.64 per share, in 2010.

R&D costs rose 32 percent to $1.02 billion from $774 million a year ago.

The firm finished the year with $537 million in cash and equivalents.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.